AstraZeneca CEO Pascal Soriot invested £7.25 million in company shares on September 14, acquiring 60,000 ordinary shares at 12,102 pence ($121.02) each. This substantial purchase, disclosed on September 18, is seen as a strong vote of confidence by Soriot, who has led AstraZeneca since October 2012. The transaction occurred after the company's share price had fallen by 20% from a record high of 15,500 pence in February, attributed to concerns over a late-stage drug trial setback and speculation linking AstraZeneca to a potential $400 billion merger with Bristol-Myers Squibb.
Soriot's purchase was part of a broader insider buying trend at AstraZeneca, with Chairman Michel Demaré also buying shares worth £300,000 on the same day at 12,121 pence. Other insiders, including Aradhana Sarin and Sharma Mani, also made purchases in September. This clustered insider activity, particularly from a CEO and Chairman, is viewed as a significant signal by market observers, indicating a belief in the company's future prospects despite recent challenges.
Analysts have largely maintained a positive outlook on AstraZeneca. UBS, for instance, cut its price target to 15,200 pence from 17,600 pence but retained a "Buy" recommendation. Berenberg also set a price target of 15,000 pence, citing the company's top-tier growth and superior R&D returns at an attractive valuation. AstraZeneca's current valuation multiple of about 14.3 times forecast core 2027 earnings is higher than the sector average of 13.1 times but remains below competitors like Novartis (15 times) and Roche (17.4 times). Goldman Sachs lifted its price target to 16,526 pence, and Bank of America Securities reiterated a "Buy" with a 16,500 pence target.
Soriot has previously stated that the company does not need large-scale M&A to achieve its medium-term goal of $80 billion in revenues. He also expressed confidence in the company's pipeline, anticipating over twenty high-value readouts within the next 18 months, despite a recent disappointment with a potential heart condition drug. AstraZeneca is focused on driving growth beyond 2030, when key cancer drugs like Imfinzi, Tagrisso, and Calquence will face patent expiration. The company's strategy involves smaller business development transactions and a continued focus on oncology, immunology, and rare diseases.
